Sage Bionetworks and AstraZeneca have entered a collaboration to investigate certain cancers using advanced computational models of disease genetics. The goal is to better match patients with appropriate treatments that might also lead to new cancer therapeutics. The partnership will leverage Sage Bionetworks’ expertise in computer models of disease genetics with AstraZeneca’s oncology expertise, including access to data on AstraZeneca’s compounds. The focus is to provide data-driven rationa...